Literature DB >> 29850188

Biomarkers in malignant mesothelioma-an unfulfilled need or a waste of resources?

Robin Cornelissen1, Joachim G J V Aerts1.   

Abstract

Year:  2018        PMID： 29850188      PMCID： PMC5949439          DOI： 10.21037/jtd.2018.03.128

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  19 in total

Review 1.  Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials.

Authors:  Gordon C S Smith; Jill P Pell
Journal:  BMJ       Date:  2003-12-20

Review 2.  Current Treatment of Mesothelioma: Extrapleural Pneumonectomy Versus Pleurectomy/Decortication.

Authors:  Andrea S Wolf; Raja M Flores
Journal:  Thorac Surg Clin       Date:  2016-08       Impact factor: 1.750

3.  Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.

Authors:  Gérard Zalcman; Julien Mazieres; Jacques Margery; Laurent Greillier; Clarisse Audigier-Valette; Denis Moro-Sibilot; Olivier Molinier; Romain Corre; Isabelle Monnet; Valérie Gounant; Frédéric Rivière; Henri Janicot; Radj Gervais; Chrystèle Locher; Bernard Milleron; Quan Tran; Marie-Paule Lebitasy; Franck Morin; Christian Creveuil; Jean-Jacques Parienti; Arnaud Scherpereel
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321

4.  Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.

Authors:  Jan P van Meerbeeck; Rabab Gaafar; Christian Manegold; Rob J Van Klaveren; Eric A Van Marck; Mark Vincent; Catherine Legrand; Andrew Bottomley; Channa Debruyne; Giuseppe Giaccone
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

Review 5.  Checkpoint Blockade in Lung Cancer and Mesothelioma.

Authors:  Lysanne A Lievense; Daniel H Sterman; Robin Cornelissen; Joachim G Aerts
Journal:  Am J Respir Crit Care Med       Date:  2017-08-01       Impact factor: 21.405

6.  A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.

Authors:  M E R O'Brien; D Watkins; C Ryan; K Priest; C Corbishley; A Norton; S Ashley; N Rowell; R Sayer
Journal:  Ann Oncol       Date:  2005-11-29       Impact factor: 32.976

7.  Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma.

Authors:  A Scherpereel; P Astoul; P Baas; T Berghmans; H Clayson; P de Vuyst; H Dienemann; F Galateau-Salle; C Hennequin; G Hillerdal; C Le Péchoux; L Mutti; J-C Pairon; R Stahel; P van Houtte; J van Meerbeeck; D Waller; W Weder
Journal:  Eur Respir J       Date:  2009-08-28       Impact factor: 16.671

8.  Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.

Authors:  Raja M Flores; Harvey I Pass; Venkatraman E Seshan; Joseph Dycoco; Maureen Zakowski; Michele Carbone; Manjit S Bains; Valerie W Rusch
Journal:  J Thorac Cardiovasc Surg       Date:  2008-02-14       Impact factor: 5.209

9.  Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study.

Authors:  Tom Treasure; Loic Lang-Lazdunski; David Waller; Judith M Bliss; Carol Tan; James Entwisle; Michael Snee; Mary O'Brien; Gill Thomas; Suresh Senan; Ken O'Byrne; Lucy S Kilburn; James Spicer; David Landau; John Edwards; Gill Coombes; Liz Darlison; Julian Peto
Journal:  Lancet Oncol       Date:  2011-06-30       Impact factor: 41.316

10.  Pleural mesothelioma and lung cancer risks in relation to occupational history and asbestos lung burden.

Authors:  Clare Gilham; Christine Rake; Garry Burdett; Andrew G Nicholson; Leslie Davison; Angelo Franchini; James Carpenter; John Hodgson; Andrew Darnton; Julian Peto
Journal:  Occup Environ Med       Date:  2015-12-29       Impact factor: 4.402
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.